cyclic nucleotide phosphodiesterase
Apremilast: first global approval.
Auckland, New Zealand. In Drugs, 2014
Apremilast (Otezla(®)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet's syndrome, atopic dermatitis, and rheumatoid arthritis.
From PDE3B to the regulation of energy homeostasis.
Lund, Sweden. In Curr Opin Pharmacol, 2011
PDE3B appears to be an important actor in regulation of energy metabolism and energy intake. Is inhibition of PDE3B a possible target for treatment of obesity or type 2 diabetes mellitus? [REVIEW]